Therapeutic Goods (Charges) Amendment Act 1993

Overview

The Therapeutic Goods (Charges) Amendment Act 1993 was enacted by the Parliament of Australia to amend the Therapeutic Goods (Charges) Act 1989, addressing the need for harmonisation of therapeutic goods regulation between the federal and state jurisdictions. This amendment was introduced to ensure that charges related to the registration and listing of therapeutic goods, as well as the issuance of licences under corresponding state laws, align with those specified under the federal Therapeutic Goods Act 1989. The overarching policy objective of this Act is to streamline and unify the regulatory framework for therapeutic goods across Australia, reducing discrepancies and ensuring consistent application of charges. This legislative effort is a step towards enhancing regulatory efficiency and coherence in the oversight of therapeutic goods, ultimately aimed at protecting public health and safety.

Scope and Application

The Therapeutic Goods (Charges) Amendment Act 1993 serves to modify the Therapeutic Goods (Charges) Act 1989, focusing on the financial aspects of therapeutic goods regulation. This Act applies to entities and individuals involved in the registration, listing, and licencing of therapeutic goods in Australia, including manufacturers, importers, and distributors of such goods. The legislative amendments ensure that when therapeutic goods are included in the Register or listed under a corresponding State law, they are treated as if they were registered or listed under the Therapeutic Goods Act 1989. Similarly, licenses issued under corresponding State laws are treated as if they were issued under the Therapeutic Goods Act 1989. The Act has a national jurisdictional reach as it pertains to the Commonwealth of Australia and its interaction with state laws. While the Act itself outlines these modifications, it may be further extended or restricted through subordinate instruments, which could include regulations or guidelines issued under the authority of the Principal Act.

Key Provisions

The Therapeutic Goods (Charges) Amendment Act 1993 (Act) is an amendment to the Therapeutic Goods (Charges) Act 1989, which primarily concerns the regulation of therapeutic goods within Australia. The Act introduces changes to the existing charges framework by modifying Section 4 of the Principal Act, which is the Therapeutic Goods (Charges) Act 1989 (section 3). Specifically, the Act amends the criteria under which certain therapeutic goods can be considered registered or listed, and when a licence can be deemed issued under the Therapeutic Goods Act 1989, if they are included in the Register for purposes of corresponding State laws. This alignment ensures that goods registered under state laws are treated equivalently to those registered under federal legislation. The obligations imposed by the Therapeutic Goods (Charges) Amendment Act 1993 primarily concern the registration and listing of therapeutic goods, as well as the issuance of licences. According to the Act, if goods are included in the Register under certain provisions of the Therapeutic Goods Act 1989, they must be treated as if they were registered or listed under the Act, depending on the state law's requirements (subsection 3(3) and 3(4)). Similarly, if a licence is issued by the Secretary for purposes of corresponding State laws, it must be treated as if it had been issued under the Therapeutic Goods Act 1989 (subsection 3(5)). These provisions ensure that the regulatory oversight of therapeutic goods is consistent across both federal and state jurisdictions. Failure to comply with the obligations and requirements set out in the Therapeutic Goods (Charges) Amendment Act 1993 could lead to significant legal consequences. While the Act itself does not explicitly outline specific offences or penalties for non-compliance, breaches of the Therapeutic Goods Act 1989, which the Amendment Act seeks to harmonise with, could result in civil or criminal penalties. For example, under the Therapeutic Goods Act 1989, unauthorised advertising of therapeutic goods can incur fines of up to $22,200 for individuals and $111,000 for bodies corporate, as well as potential imprisonment. The consequences for non-compliance are thus severe, emphasising the importance of adhering to the regulatory framework established by both the Principal Act and the Amendment Act.